Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs GLPG 1690 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ISABELA 1
  • Sponsors Galapagos NV
  • Most Recent Events

    • 17 Dec 2018 According to a Galapagos NV media release, the company has dosed its first patient in the worldwide ISABELA phase 3 program (ISABELA 1 and ISABELA 2) with autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF).
    • 17 Oct 2018 Status changed from planning to recruiting.
    • 12 Apr 2018 According to a Galapagos NV media release, this ISABELA program is expected to start dosing in the second half of 2018. A total of 1500 patients are planned to enrol in this program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top